{
  "id": 20092977,
  "title": "Mbx Biosciences ceo Steven Hoerter sells $268,234 in shares",
  "url": "https://urgent.news/2026/11/15/mbx-biosciences-ceo-steven-hoerter-sells-268-234-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-15T01:01:19.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/mbx-biosciences-ceo-steven-hoerter-sells-268234-in-shares-93CH-5027612"
  },
  "original_language": "en",
  "account": "Steven L. Hoerter, the Chairman, President, and CEO of MBX Biosciences, Inc., divested 4,893 shares of the company's common stock for a total value of $268,234 on November 10, 2026. The shares were sold at a weighted average price of $54.82 per share, within a price range of $51.52 to $55.29. This transaction was conducted to settle tax liabilities arising from the vesting of restricted stock units under a mandatory sell-to-cover agreement with the company. Currently, the stock is trading at $55.94, marking an 8.9% gain over the past week and a 126% return over the previous year. Post-transaction, Hoerter directly owns 78,045 shares of MBX Biosciences common stock, with an additional 20,000 shares held indirectly through the Steven L Hoerter Revocable Trust. According to InvestingPro analysis, the stock is currently fairly valued. MBX Biosciences has garnered significant attention from several analyst firms. Citizens has assigned a Market Outperform rating with a price target of $86, citing promising data from MBX-4291, an injectable obesity treatment. Truist Securities has maintained a Buy rating with a price target of $88, highlighting the drug's favorable risk/reward profile ahead of its data readout expected in Q4 2026. Stifel has also increased its price target to $84, retaining a Buy rating due to positive Phase 1 trial results for MBX-4291, including a smooth pharmacokinetic profile and high tolerability. The company has also appointed Peter Radovich as an independent director, bringing the total board members to eight, per a recommendation from the Nominating and Corporate Governance Committee.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}